Tencent and Gilead Sciences took part in a round that will fund clinical trials for three of Vaccitech's vaccine product candidates.

OSF Healthcare Ventures contributed to a $102m series D round for Inflammatix, a developer of diagnostics systems for detecting infections.

Novo co-led an $81.5m round for the gene therapy developer that included Sarepta Therapeutics, UCB Ventures, Takeda Ventures and Alexandria Venture Investments.

UF Innovate Ventures has contributed to a series B round for StrideBio, partially based on research into gene therapies at University of Florida.

Novo Nordisk, Insulet and Mayo Clinic helped the diabetes monitoring technology provider push its overall funding past $100m.

D1 Capital Partners has led a $102m series D round for Inflammatix, whose existing shareholders include Stanford-StartX Fund.

This is the first in a series of quarterly publications for the Global Health Council looking at drug development, healthcare providers such as hospitals and digital health, payments and patient wellness. This first article looks at the implications of the disease treatments coming out of advanced research and artificial intelligence and the broader shift to digitalisation in healthcare. The next issue will focus on the providers of healthcare.

The spinout’s technology was fundamental to Oxford’s covid vaccine, prompting OSI and Future Planet Capital to back a $168m round.

Binoy Bhansali was previously at Sandbox Industries, which manages $1.2bn across four funds for health insurer Blue Cross Blue Shield.

IBM Ventures participated in a $20m round for the neurological disease diagnostics technology spinout of Tel Aviv University.